Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2023-11-15 Report Publication Anno…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Form 6-K- financial results for the nine months ended September 30, 2023
Report Publication Announcement Classification · 95% confidence The document is a short regulatory filing from XTL Biopharmaceuticals Ltd submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on...' followed by a filename (ea188494-6k_xtlbiopharmaEDGAR2_Bannerless_isa.pdf). Per the 'Menu vs Meal' rule, since this document is a brief notification announcing the availability of an attached report rather than the report itself, it is classified as a Report Publication Announcement (RPA). FY 2023
2023-11-15 English
REPORT OF FOREIGN PRIVATE ISSUER
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by XTL Biopharmaceuticals Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It contains detailed financial results for the nine months ended September 30, 2023, including unaudited consolidated statements of financial position and comprehensive income. The document includes management commentary on financial performance, operational updates, and forward-looking statements. The presence of substantive financial data and analysis for a period shorter than a full fiscal year (nine months) indicates this is an interim or quarterly report. The Form 6-K is commonly used by foreign private issuers to report interim financial results. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2023-11-15 English
6K-Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency; Confirms that it has not Experienced any Disruption to its Business Operations in Israel
Regulatory Filings Classification · 98% confidence The document is explicitly titled "Form 6-K" and is filed by a Foreign Private Issuer ("XTL Biopharmaceuticals Ltd.") pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 for the month of October, 2023. Form 6-K is the standard SEC filing used by foreign private issuers to report material information that they are required to disclose to their home country's stock exchange or make public in their home country. This type of filing is generally considered a miscellaneous regulatory filing that does not fit neatly into the specific categories like 10-K (Annual Report) or ER (Earnings Release). Since it is a mandatory, non-standardized disclosure document for a foreign issuer, the most appropriate classification among the provided options is the general regulatory fallback category, RNS (Regulatory Filings). Although it contains press releases, the primary document structure is the Form 6-K wrapper itself.
2023-10-20 English
6K-Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency; Confirms that it has not Experienced any Disruption to its Business Operations in Israel
Report Publication Announcement Classification · 99% confidence The document is a short regulatory filing announcement dated 20/10/2023, issued by XTL BIOPHARMACEUTICALS LTD, referencing the Israel Securities Authority and the Tel Aviv Stock Exchange. Crucially, the text states, "Attached hereto is a report on*\_______* *ea187052-6k_xtlbiopharmaEDGAR2_Bannerless_isa.pdf*". The filename contains '6k', suggesting the attached document is a 10-K, but the current document itself is merely announcing the publication and attaching the report. According to Rule 2, when a document is short and announces the publication of a report, it should be classified as a Report Publication Announcement (RPA).
2023-10-20 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes press releases about Nasdaq notification and business operations but does not contain detailed financial statements or comprehensive financial analysis. The document length is short (2009 characters), and it mainly serves as a regulatory announcement of events and press releases. According to the rules, such filings that do not contain full financial reports but are regulatory announcements fall under Regulatory Filings (RNS).
2023-10-20 English
Financial results for the six months ended June 30, 2023
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filed with the SEC by XTL Biopharmaceuticals Ltd. It contains unaudited consolidated financial statements (balance sheet and income statement) for the six-month period ended June 30, 2023. Since it provides substantive financial data for an interim period (less than a full fiscal year) and is not merely an announcement or certification, it is classified as an Interim/Quarterly Report. H1 2023
2023-08-10 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.